Tildrakizumab 100 mg (one 1-ml injection of 100 mg/ml (DrugBank: Tildrakizumab)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 271 | Ankylosing spondylitis | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03552276 (ClinicalTrials.gov) | July 11, 2018 | 4/5/2018 | A Long Term Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis. | A Multiple-Dose, Long-Term Extension Study to Demonstrate the Safety and Efficacy of Tildrakizumab in Subjects With Psoriatic Arthritis and Ankylosing Spondylitis or Non-Radiographic Axial Spondyloarthritis Who Have Previously Completed Studies With Tildrakizumab. | Psoriatic Arthritis;Ankylosing Spondylitis;Non-Radiographic Axial Spondyloarthritis | Drug: tildrakizumab 200 mg (two 1-mL injections of 100 mg/mL);Drug: tildrakizumab 100 mg (one 1-mL injection of 100 mg/mL + 1 mL placebo) | Sun Pharma Global FZE | NULL | Active, not recruiting | 18 Years | N/A | All | 540 | Phase 2;Phase 3 | United States;Argentina;Hungary;Mexico;Poland;Russian Federation;Spain;Ukraine |